Noninvasive Stereotactic Radiotherapy for PADN in an Acute Canine Model of Pulmonary Arterial Hypertension

Xu, Wei; Wang, Ding-yu; Chen, Zi-yin; Gao, Qiang; Zou, Yi-lun; Sun, Dang-hui; Zhang, Song; Zhao, Xin-bo; Gong, Yong-tai; Zhang, Yun; Zhang, Da-xin; Li, Yue

doi:10.1016/j.jacbts.2023.09.013

Cited by 1 publication

(1 citation statement)

References 38 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-pharmacological PH therapies such as sympathetic modulation and neurostimulation of the parasympathetic nerves are under investigation. Sympathetic modulation has been pursued with various methods such as sympathetic ganglion block, renal sympathetic denervation, and pulmonary artery denervation (PADN), which are accomplished by multiple techniques such as radiofrequency ablation or high-energy ultrasound [170][171][172][173]. Numerous studies with animal models of PH have reported that reducing sympathetic activity attenuates pulmonary vascular remodeling, reducing hemodynamic parameters including right ventricular pressure and mPAP, and reducing pulmonary wall thickness [170,[174][175][176][177][178][179][180][181].…”

Section: Non-pharmacological Therapies: Sympathetic Activity Modulati...mentioning

confidence: 99%

Pulmonary Hypertension: Pharmacological and Non-Pharmacological Therapies

Tsai,

Malik,

Tjen-A-Looi

2024

Preprint

View full text Add to dashboard Cite

Pulmonary hypertension (PH) is a severe and chronic disease characterized by increased pulmonary vascular resistance and remodeling often precipitating right-sided heart dysfunction and death. Although the condition is progressive and incurable, current therapies for the disease focus on multiple different drugs and general supportive therapies to manage symptoms and prolong survival, ranging from medications more specific to pulmonary arterial hypertension (PAH) to exercise training. Moreover, there are multiple studies exploring novel experimental drugs and therapies including unique neurostimulation, to help better manage the disease. Here we provide a narrative review focusing on current PH treatments that target multiple underlying biochemical mechanisms, including but not limited to imbalances in vasoconstrictor-vasodilator and autonomic nervous system function, inflammation, and bone morphogenic protein (BMP) signaling. We also focus on the potential of novel therapies for managing PH, focusing on multiple types of neu-rostimulation including acupuncture. Lastly, we also touch upon the disease’s different subgroups, clinical presentations and prognosis, diagnostics, demographics, and cost.

show abstract